Press releases 2014

Gothenburg, Sweden, 2014-12-19 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the US Patent and Trademark Office has declared its intention to approve the Company's patent application for a genetically modified adenovirus vector. The vector is, among other things, intended to (...)

Gothenburg, Sweden, 2014-12-15 09:04 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the United States Patent and Trademark Office (USPTO) has submitted a "Notice of Allowance" regarding patent application 13/522,741 and thereby intends to approve Immunicum's patent to protect  (...)

Gothenburg, Sweden, 2014-12-03 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today published an interim report on the safety and survival data from the ongoing phase I/II study with INTUVAX in patients with primary liver cancer. Based on the results achieved so far, an independent safety co (...)

Gothenburg, Sweden, 2014-12-03 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced continued promising data from a phase I/II trial in patients with metastatic renal cell carcinoma. The median survival in the subgroup of five individuals who were initially classified as high-risk  (...)

Gothenburg, Sweden, 2014-11-26 08:30 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the company's founder and Chief Scientific Officer, Alex Karlsson-Parra, has been awarded the Athena Prize for his creative and innovative development of therapeutic cancer vaccines, which cons (...)

Gothenburg, Sweden, 2014-10-27 14:15 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that it has acquired the patent rights to a genetically modified adenovirus vector. The vector is primarily intended to be used for efficient loading of vaccine cells by a variety of tumor antigens  (...)

Gothenburg, Sweden, 2014-09-12 12:58 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that updated survival data from a completed Phase I/II study of INTUVAX will be presented on September 15 at the 3rd Annual Cancer Vaccines Conference in London. In this study, the therapeutic canc (...)

Gothenburg, Sweden, 2014-06-03 08:45 CEST (GLOBE NEWSWIRE) -- Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa, Japan, Hong Kong or New Zealand or in any jurisdiction in which the distribution or release of this  (...)

Gothenburg, Sweden, 2014-06-02 08:30 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), a biopharmaceutical company developing therapeutic cancer vaccines, today announced that phase I/II data has been presented during a general poster session at the American Society of Clinical Oncology's (ASCO) 20 (...)

Gothenburg, Sweden, 2014-05-26 12:24 CEST (GLOBE NEWSWIRE) -- Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa, Japan, Hong Kong or New Zealand or in any jurisdiction in which the distribution or release of this  (...)

Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell carcinoma

Gothenburg, Sweden, 2014-05-21 13:44 CEST (GLOBE NEWSWIRE) -- In addition to continued c (...)

Gothenburg, Sweden, 2014-05-15 07:43 CEST (GLOBE NEWSWIRE) -- Immunicum announces that the abstract on INTUVAX clinical data has been released for ASCO 2014

- Being accepted to present at the most prestigious cancer conference in the world gives us a great opportunity to showcase Immunicum's te (...)

Göteborg, Sweden, 2014-04-15 10:33 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ) ("Immunicum") has decided to change the date of publication of its interim report for the period 1 July 2013 - 31 March 2014. The new date of publication is 7 May 2014. The previously announced date of publication was 20 (...)

Göteborg, Sweden, 2014-04-02 08:50 CEST (GLOBE NEWSWIRE) -- Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa, Japan, Hong Kong or New Zealand or in any jurisdiction in which the distribution or release of this pr (...)

Göteborg, Sweden, 2014-03-31 08:56 CEST (GLOBE NEWSWIRE) -- Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12 patients with newly diagnosed kidney cancer, treated with the cancer vaccine INTUVAX®. No vaccin (...)

Göteborg, Sweden, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) -- Immunicum today announced that an abstract has been approved to for presentation at the American Society of Clinical Oncology's's, ASCO, annual convention held in Chicago May 30-June 3, 2014.

The abstract, with title "Intratumoral  (...)

Gothenburg, Sweden, 2014-03-06 08:40 CET (GLOBE NEWSWIRE) -- Promising data for Immunicum's CD70-technology for adoptive immunotherapy are today being published in a scientific journal. The results indicate a robust method to expand tumor-specific T-cells with improved quality in comparison wit (...)

Gothenburg, Sweden, 2014-02-18 08:59 CET (GLOBE NEWSWIRE) -- Second half of 2013 compared with the same period in 2012

Profit/Loss

The net loss for the period July 1 - December 31, 2013 amounted to - 5 583 KSEK, compared to - 2 177 KSEK for the same period in 2012. Earnings per share amounted t (...)